RadNet, Inc. · NASDAQ:RDNT
RadNet — Investor Presentation (February 2010)
23 slides from RadNet's investor presentation, February 2010
Slide 1: February 2010 NASDAQ: RDNT
February 2010 NASDAQ: RDNT
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the benefits of the merger of Primedex Health Systems, Inc. and Radiologix, Inc. to form RadNet, Inc., expected syner
Slide 3: Presenters
Presenters Howard Berger, M.D. President and Chief Executive Officer Mark Stolper Executive Vice President and Chief Financial Officer 2
Slide 4: I. Introduction
I. Introduction II. Diagnostic Imaging Industry Overview III. Overview of RadNet IV. Financial Information and Core Strategy 3
Slide 5: RadNet Summary
RadNet Summary Largest national owner and operator of fixed-site diagnostic imaging centers, with 175 locations Founded as a one center CA operation in 1984 Largest fixed-site medical imaging center company in the U.S. Have emerged as the fastest growing consolidator in the highly fragmented
Slide 6: RadNet Summary (cont.)
RadNet Summary (cont.) Only imaging center player to provide exclusive managed care capitation arrangements with prominent medical groups and Independent Physician Associations (IPAs) Provides “ sticky”and predictable revenue base and substantial “ pull-through”business Over 750,000 lives mana
Slide 7: I. Introduction
I. Introduction II. Diagnostic Imaging Industry Overview III. Overview of RadNet IV. Financial Information and Core Strategy 6
Slide 8: Diagnostic Imaging: A Large and Growing Market
Diagnostic Imaging: A Large and Growing Market National imaging market is estimated at $100 billion Highly fragmented industry Approximately 6,000 outpatient diagnostic imaging centers in the US Advanced imaging procedures growing quickly MRI and CT: 3%-5% CAGR PET/CT: >5% CAGR Demand
Slide 9: Types of Imaging Exams "Modalities"
Types of Imaging Exams “Modalities” MRI –Produces high Nuclear Medicine – resolution cross- Producers images of sectional images of soft anatomical structures. tissue. Applications: Applications: Assesses brain, spinal cord and organ function in heart, interior ligaments. kidney, thyroid and bones.
Slide 10: DRA and Credit Crises Are Driving Consolidation
DRA and Credit Crises Are Driving Consolidation Deficit Reduction Act of 2005 (“ DRA” ) went into effect on January 1, 2007 Primarily impacted Medicare reimbursement for MRI, CT, and PET/CT modalities Lower Medicare reimbursement has made it difficult for “ mom-and-pop”operators Not well cap
Slide 11: I. Introduction
I. Introduction II. Diagnostic Imaging Industry Overview III. Overview of RadNet IV. Financial Information and Core Strategy 10
Slide 12: We are Regionally Focused
We are Regionally Focused 175 facilities located predominantly in the concentrated markets of California, Maryland, Delaware, New Jersey and New York NY 19 NJ –8 DE - 12 CA KS 97 2 MD - 34 FL 3 11
Slide 13: Multi-Modality Focused
Multi-Modality Focused The vast majority of our centers are multi-modality Extensive offering of routine imaging procedures partially insulates us from reimbursement cuts, which generally affect (like the DRA) MRI, CT and PET modalities disproportionally Scan Scan Volume Volume by by Modality Mo
Slide 14: Diversified Payor Mix
Diversified Payor Mix Exclusive capitation business decreases the Combined Company’ s exposure to potential pricing changes from commercial payors Capitation dilutes the % of our business from each of the other payor classes Capitation price escalators create “ built in”increasing reimbursemen
Slide 15: Capitated Contracts Create a Barrier to Entry
Capitated Contracts Create a Barrier to Entry RadNet has over 25 capitated contracts with California physician groups representing approximately 15% of our revenue We receive a per-member-per-month fixed price for exclusively providing outpatient imaging to over 750,000 lives in CA Exclusive n
Slide 16: RadNet's BreastLink: Breast Disease Management
RadNet’ s BreastLink: Breast Disease Management Acquired renowned specialty breast medical oncology and breast surgery practices in Southern California Imaging is an integral part of identifying, diagnosing, staging and tracking the progression of breast cancer BreastLink provides patients wit
Slide 17: Experienced Management Team
Experienced Management Team Howard Berger, MD –Chairman and Chief Executive Officer Mark Stolper –Chief Financial Officer Co-founded RadNet in 1981 Deep experience in investment banking and private Over 25 years of experience in the equity development and management of Dillon Read investment ban
Slide 18: I. Introduction
I. Introduction II. Diagnostic Imaging Industry Overview III. Overview of RadNet IV. Financial Information and Core Strategy 17
Slide 19: Strong Revenue and EBITDA Performance
Strong Revenue and EBITDA Performance Revenue EBITDA Trailing 12 Mo. Revenue = $523.3mm Trailing 12 Mo. EBITDA = $102.9mm* * Adjusted for $1.5mm non-cash charge for increasing the contractual allowance on Accounts Receivable from services provided in 2008 and prior fiscal years. Adjustment occurred
Slide 20: Strong Year to Date Performance
Strong Year to Date Performance Revenue EBITDA * * +6.1%Growth +5.9%Growth Revenue increased 6.1% to $394.1* million vs. $371.4 million for the 9 months of 2008 Adjusted EBITDA increased 5.9% to $80.4* million vs. $75.9 million for the 9 months of 2008 MRI volume increased 9.9%, CT volume incr
Slide 21: Elements of Core Strategy
Elements of Core Strategy Focus on free cash flow generation and deleveraging the balance sheet Continue to drive growth through marketing, contracting and newer initiatives such as mammography and women’ s health Continue to complete very accretive tuck-in acquisitions Many underperforming
Slide 22: Summary Valuation Metrics: RDNT
Summary Valuation Metrics: RDNT Valuation Metrics Based Upon Anticipated 2009 EBITDA 1 Equity Market Capitalization @ $2.19 per share $ 79.2 mm 2 Net Debt 456.1 mm Current Enterprise Valuation $ 535.3 mm Trailing 12 Mo. EBITDA - 9/30/09 $ 102.9 mm* 2009 RadNet EBITDA Guidance $105-110 mm Enterprise
Slide 23: Summary: Near Term Outlook is Encouraging
Summary: Near Term Outlook is Encouraging # of scans in industry is projected to continue to grow Abundant consolidation opportunities at attractive multiples Advantages of RadNet’ s scale and cost structure are becoming more important Weaker competitors beginning to close RadNet has a lea